CareDx, Inc.（CDNA）財務資料CDNACareDx, Inc.

CareDx, Inc. (CDNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Testing Service revenue, accounting for 75.7% of total sales, equivalent to $99.93M. Other significant revenue streams include Digital and other revenue and Product revenue. Understanding this composition is critical for investors evaluating how CDNA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, CareDx, Inc. maintains a gross margin of 73.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 85.81%, while the net margin is 83.85%. These profitability ratios, combined with a Return on Equity (ROE) of 29.49%, provide a clear picture of how effectively CDNA converts its operational activities into shareholder value.

In the context of the broader market, CDNA competes directly with industry leaders such as CELC and IRTC. With a market capitalization of $3.35B, it holds a significant position in the sector. When comparing efficiency, CDNA's gross margin of 73.50% stands against CELC's N/A and IRTC's 72.80%. Such benchmarking helps identify whether CareDx, Inc. is trading at a premium or discount relative to its financial performance.

CareDx has shown strong revenue growth, with Q2 2026 revenue at $131.95 million, up from $117.7 million in Q1 2026. The net income for Q2 2026 was $110.64 million, reflecting a significant recovery from previous quarters.